文献速递临床试验与 GCP基础与转化研究

阿托伐他汀钙盐与辛伐他汀酸钠盐治疗活动性白癜风皮损复色评估(EVRAAS):随机对照试验研究方案

The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-01-25

EVRAAS 是一项单中心、随机、双盲、安慰剂对照的先导研究,计划入组至少 24 例活动性非节段性白癜风患者。患者双上下肢皮损分别外用 1% 辛伐他汀酸钠盐软膏、1% 阿托伐他汀钙盐软膏与赋形剂软膏,在基线及第 4、8、12 周用 BSA 和 VASI 评分并拍照评估。研究旨在评估局部外用他汀的安全性和疗效。

要点

  • 活动性非节段性白癜风患者双上下肢皮损分别外用 1% 辛伐他汀酸钠盐、1% 阿托伐他汀钙盐与赋形剂软膏。
  • 基线及第 4、8、12 周用 BSA 和 VASI 评分并拍照评估皮损复色。
  • 该研究首次评估局部外用他汀治疗非节段性白癜风的安全性和疗效。

核心结论

  • 研究旨在评估辛伐他汀和阿托伐他汀对非节段性白癜风患者皮损的影响。
  • 该研究为首次评估局部外用他汀治疗非节段性白癜风安全性和疗效的研究。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照先导研究。
  • 计划入组至少 24 例活动性非节段性白癜风患者,皮损位于双上下肢。
  • 患者双上下肢分别外用 1% 辛伐他汀酸钠盐软膏、1% 阿托伐他汀钙盐软膏与赋形剂软膏。
  • 在基线及第 4、8、12 周用 BSA 和 VASI 评分评估,并拍照经 NIS-Elements 软件处理。

临床怎么用

  • 目前白癜风局部治疗包括钙调神经磷酸酶抑制剂和糖皮质激素,疗效欠佳且存在成本高或潜在危险不良反应。
  • 口服他汀在白癜风患者中仅有两项临床试验,数据稀缺;因全身毒性风险,研究者推荐局部给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitiligo is a chronic skin disorder presenting with depigmentation, the pathogenesis of which is complex but the autoimmune theory is now preferred. Multiple immunologic processes, including stimulation of the T-helper (Th)1 response, formation of autoreactive melanocyte-specific CD8+ T lymphocytes, a decrease in the blood concentration of T regulatory (Treg) cells, and an increase in interleukin (IL)-17 and interferon (IFN) concentration, have been shown to contribute to vitiligo progression and maintenance. The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with nonsegmental vitiligo (NSV). According to available data, statins act through several immunological pathways, potentially reversing undesirable phenomena underlying autoimmune vitiligo pathogenesis. METHODS/DESIGN: A study has been designed as a single-center, randomized, double-blind, placebo-controlled pilot study with the enrollment of at least 24 active NSV patients presenting with vitiligous lesions on both upper and lower limbs. The clinical effects of ointments containing 1% simvastatin-acid sodium salt or 1% atorvastatin calcium salt applied on a preselected limb will be assessed in comparison with vehicle ointment applied on the opposite limb. All study participants will undergo clinical evaluation using body surface area (BSA) and Vitiligo Area Scoring Index (VASI) scales at baseline and at weeks 4, 8, and 12 time points. A precise assessment of skin lesions will be performed using photographic documentation obtained during each study visit and processed with NIS-Elements software. DISCUSSION: Currently available vitiligo topical therapeutic approaches including calcineurin inhibitors and corticosteroids remain poorly effective and are associated with either relatively high cost or potentially dangerous adverse effects. The clinical application of orally administrated statins, widely used as systemic cholesterol-lowering agents, in vitiligous patients has only been tested in two clinical trials; however, data on their potential usefulness is scarce. Moreover, due to a high risk of clinically significant toxicity, topical administration was recommended by researchers. This study is the first to evaluate safety and efficacy of the topical use of statins in patients presenting with NSV. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03247400 . Registered on 05 August 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Niezgoda A, Winnicki A, Kosmalski T, et al. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30683146. doi:10.1186/s13063-018-3168-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。